Antibody‑drug conjugate specialist Tubulis closed a €308 million (≈$356M) Series C to expand clinical development of TUB‑040 and its ADC platform. The funding positions the company to test its lead program in earlier lines, additional tumor types, and accelerate pipeline programs ahead of planned data presentations at major oncology meetings. Investors underscored Tubulis’ in‑house ADC design and higher drug‑to‑antibody ratio approach as drivers for the large round. The raise ranks among the largest private biotech financings in Europe this year and will fund clinical operations and manufacturing scale‑up.